Impact of Administering Umbilical Cord-derived Mesenchymal Stem Cells to Cynomolgus Monkeys with Endometriosis
Overview
Authors
Affiliations
Purpose: This study aimed to explore whether umbilical cord-derived mesenchymal stem cells (UC-MSCs) could be used as a therapeutic resource for endometriosis.
Methods: Of seven cynomolgus monkeys with endometriosis, five were administered UC-MSCs (intervention group) and two were administered saline (control group). First, intravenous US-MSC treatment was administered for three months. Second, weekly intravenous US-MSC administration combined with monthly intraperitoneal US-MSC administration was conducted for 3 months. Finally, weekly intraperitoneal US-MSC administration was conducted for 3 months. The dose of UC-MSCs was set to 2 × 10 cells/kg for all administration routes. Laparoscopic findings and serum cancer antigen 125 (CA125) levels were also evaluated. The Revised American Society for Reproductive Medicine classification was used for laparoscopic evaluation.
Results: Laparoscopic findings showed exacerbation of endometriosis after intraperitoneal UC-MSC administration, although no changes were observed in the control group. Intravenous UC-MSC administration decreased the level of CA125 in all monkeys; however, the difference was not significant. Intraperitoneal UC-MSC administration significantly exacerbated endometriosis compared with intravenous administration ( = 0.02).
Conclusions: This study revealed that intraperitoneal UC-MSC administration exacerbates endometriosis in a nonhuman primate model of the disease.
Mesenchymal stem cells: Guardians of women's health.
Gao G, Li L, Li C, Liu D, Wang Y, Li C Regen Ther. 2024; 26:1087-1098.
PMID: 39582803 PMC: 11585475. DOI: 10.1016/j.reth.2024.10.011.
Tsuji S, Mukai T, Tsuchiya H, Iwatani C, Nakamura A, Nagamura-Inoue T Reprod Med Biol. 2023; 22(1):e12540.
PMID: 37693240 PMC: 10491929. DOI: 10.1002/rmb2.12540.